European Biopharmaceutical Review |
 |
|
|
|
|
At the cutting edge of the latest industry developments, Samedan is adept at keeping the information you need at your fingertips. EBR provides a unique platform of communication for the market across Europe, North America and the rest of the developed world. To find out what's hot in the world of of biopharmaceuticals, take a look below at the range of articles featured in this issue of EBR |
 |
| |
|
|
|
| Sandrine Cailleteau at Michel Dyens & Co believes that consolidation in the biotech industry through mergers
and acquisitions needs to accelerate in order to allow the biotech industry to grow and create value in today’s
highly volatile financial markets |
|
|
| Gavin Weir and Isabella Roberts of Simmons & Simmons discuss the funding pitfalls
that bioscience companies face as a result of worsening market conditions |
|
|
|
| Jerona Noonan at Genesys Conferencing discusses
the role of collaboration in driving ‘green’ performance |
|
|
| Bob Chandler and Gianfranco Chicco of Biosector 2 discuss how priorities are shifting for small companies,
meaning they must tailor their communications to help establish themselves in an increasingly crowded market |
|
|
|
| Jenny Littlechild at Bioapproaches discusses the commercial applications
of robust enzyme catalysts, and potential platforms for future biocatalytic processes |
|
|
| Ronald G Jubin of PBL discusses the techniques currently employed to study interferon levels
in order to help further comprehend what is a potentially very useful cytokine |
|
|
| With clinical trial analyses needing an update, Alan Phillips
at ICON Clinical Research explores Bayesian methods for re-thinking biostatistics
|
|
|
| Dr Jean-Yves Bonnefoy of Transgene considers the serious threat of SARS, bird flu and other highly infectious
and potentially devastating diseases such as HIV and Hepatitis C. All have led big pharmaceutical companies
to review their focus on the development of new vaccines |
|
|
| Gillian Byrne from Applied Cytometry explains how modern analysis software
is dealing with the tide of data generated by a new generation of flow cytometers |
|
|
|
|
|
Lisette Oversteegen and Clare Davies at Datamonitor predict that the autoimmune disease market
is going to be one of the fastest growing therapy areas in terms of sales in the next few years |
|
|
| Disease prevention by vaccination saves millions of lives every year, yet millions more die worldwide due to
inadequate vaccine supply, and the world faces increasing threats of pandemics such as influenza and SARS.
Björn Lundgren at GE Healthcare discusses how these factors have highlighted a need for the development
of new vaccines and improved manufacturing processes |
|
|
|
|
Michael Rosenberg of Health Decisions examines the operational aspects
of adaptive research – a traditionally overlooked component of clinical trials |
|
|
|
Michael Gotz of MLG Consulting explores the regulatory responsibilities shippers
face when transporting infectious pathogens by air |
|
|
| Ilesh Sanathra at Pharmalink Consulting Ltd discusses whether change control is an appropriate regulatory tool |
|
|
|
Anthony Warnock Smith and Natalie Kingston at Morgan Lewis examine the Advanced Therapies Regulation,
which was finally introduced by the European Commission in November 2007 |
|
|
|
|
Martin Shaw of Biotrin explores the potential benefits
of using cell-specific biomarkers in human renal studies |
|
|
|
Stephen Blatcher, Angus Forster, Jennifer Vondran and Ian Rhodes of PA Consulting explore the best methods
with which to realise the commercial potential of combination products and convergence therapies |
|
|
|
|
|
